Seattle, July 22, 2022 (GLOBE NEWSWIRE) — According to Coherent Market Insights, the global Enzyme Linked Immunosorbent Assay (ELISA) market is estimated to be valued at US$ 2,016.1 million in 2022 and is expected to exhibit a CAGR of 5.1% during the forecast period (2022-2030).
Key Trends and Analysis of the Global Enzyme Linked Immunosorbent Assay (ELISA) Market:
Increasing product launches by market players is expected to drive the global Enzyme Linked Immunosorbent Assay (ELISA) market over the forecast period. For instance, on March 03, 2020, Epitope Diagnostics, a medical device manufacturing company had launched immunoassay kits exclusively for the qualitative detection of COVID-19. These kits include The EDI Novel Coronavirus COVID-19 IgG ELISA Kit and EDI Novel Coronavirus COVID-19 IgM ELISA Kit. With proven results from clinical testing in China.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1505
Key Market Takeaways:
Global Enzyme Linked Immunosorbent Assay (ELISA) market is expected to exhibit a CAGR of 5.1% during the forecast period due to increasing product launches by market players in the global Enzyme Linked Immunosorbent Assay (ELISA) market. For instance, on February 18, 2021, Agilent Technologies Inc., a manufacturing company of analytical instrumentation development had announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit intended for the…
